Lead Product(s) : Corallopyronin A
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : The Global Health Innovative Technology
Deal Size : $5.9 million
Deal Type : Funding
USD 10.8 Mn Invested in New Drug Development for Malaria with Japanese Pharma Partners
Details : The net proceeds will be used for the preclinical development of the macrofilaricide corallopyronin A (CorA) for the treatment of onchocerciasis and lymphatic filariasis.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Undisclosed
May 08, 2024
Lead Product(s) : Corallopyronin A
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : The Global Health Innovative Technology
Deal Size : $5.9 million
Deal Type : Funding
LOOKING FOR A SUPPLIER?